Clinical trials: DLBCL, Diffused Large B Cell Lymphoma
Hematology, Diffused Large B Cell Lymphoma
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231.
- Trial name
- DOMAIN (NCT07065344)
- Where
- 21 sites in Egypt, Iraq and 8 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Non Hodgkin Lymphoma
A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy.
- Trial name
- ACCEPT (NCT03571308)
- Testing
- R-CHOP + acalabrutinib
- Where
- 7 sites in United Kingdom
- Volunteers
- 39 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Primary Central Nervous System Diffusing Large Cell Lymphoma
The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma.
- Trial name
- NCT07007611
- Volunteers
- 76 people
- Sponsor
- jiahong Deng